UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (38464) 38464
Dissertation (97) 97
Magazine Article (91) 91
Book Chapter (64) 64
Newspaper Article (44) 44
Conference Proceeding (29) 29
Publication (17) 17
Book / eBook (12) 12
Government Document (4) 4
Book Review (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (21045) 21045
life sciences & biomedicine (19564) 19564
humans (18201) 18201
animals (17918) 17918
piperidines - pharmacology (17577) 17577
male (16609) 16609
female (10391) 10391
rats (8705) 8705
piperidines - therapeutic use (8242) 8242
pharmacology & pharmacy (7001) 7001
adult (5266) 5266
middle aged (5185) 5185
piperidines - administration & dosage (4703) 4703
mice (4680) 4680
dose-response relationship, drug (4438) 4438
neurosciences & neurology (4374) 4374
aged (4002) 4002
neurosciences (3915) 3915
piperidines - chemistry (3739) 3739
piperidines (3467) 3467
piperidines - adverse effects (3180) 3180
chemistry (2993) 2993
rats, sprague-dawley (2800) 2800
in vitro techniques (2589) 2589
physical sciences (2469) 2469
pyrazoles - pharmacology (2391) 2391
abridged index medicus (2368) 2368
time factors (2302) 2302
piperidines - chemical synthesis (2247) 2247
piperidine (2146) 2146
piperidines - metabolism (2068) 2068
structure-activity relationship (2057) 2057
rats, wistar (2039) 2039
biochemistry & molecular biology (2033) 2033
double-blind method (1937) 1937
piperidines - pharmacokinetics (1862) 1862
anesthesiology (1779) 1779
treatment outcome (1759) 1759
analysis (1664) 1664
psychiatry (1534) 1534
molecular structure (1442) 1442
indans - therapeutic use (1440) 1440
guinea pigs (1400) 1400
kinetics (1398) 1398
disease models, animal (1380) 1380
adolescent (1370) 1370
remifentanil (1341) 1341
research (1319) 1319
chemistry, medicinal (1296) 1296
oncology (1294) 1294
stereoisomerism (1283) 1283
blood pressure - drug effects (1273) 1273
brain - metabolism (1272) 1272
clinical neurology (1211) 1211
alzheimer disease - drug therapy (1210) 1210
administration, oral (1150) 1150
receptor, cannabinoid, cb1 - antagonists & inhibitors (1145) 1145
drug interactions (1131) 1131
cells, cultured (1116) 1116
clinical trials as topic (1110) 1110
donepezil (1080) 1080
dogs (1077) 1077
enzyme inhibitors - pharmacology (1054) 1054
mice, inbred c57bl (1050) 1050
cholinesterase inhibitors - therapeutic use (1032) 1032
aged, 80 and over (1006) 1006
pyridines - pharmacology (1006) 1006
heart rate - drug effects (997) 997
rats, inbred strains (984) 984
alzheimer's disease (940) 940
ligands (931) 931
cell line, tumor (929) 929
behavior, animal - drug effects (897) 897
brain - drug effects (896) 896
drug therapy (890) 890
serotonin antagonists - pharmacology (890) 890
rabbits (889) 889
old medline (864) 864
research article (862) 862
models, molecular (846) 846
piperidines - blood (842) 842
general & internal medicine (835) 835
motor activity - drug effects (820) 820
indoles - pharmacology (817) 817
drug therapy, combination (808) 808
chemistry, organic (807) 807
prospective studies (787) 787
neurons - drug effects (785) 785
binding sites (782) 782
endocrinology & metabolism (778) 778
cisapride (775) 775
rodents (768) 768
analysis of variance (758) 758
rimonabant (757) 757
young adult (740) 740
physiology (736) 736
cell biology (731) 731
chemistry, multidisciplinary (727) 727
cell line (722) 722
electric stimulation (715) 715
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (35822) 35822
German (906) 906
Japanese (885) 885
French (607) 607
Russian (402) 402
Italian (279) 279
Chinese (267) 267
Spanish (223) 223
Polish (123) 123
Portuguese (102) 102
Czech (50) 50
Danish (38) 38
Hungarian (26) 26
Slovak (24) 24
Ukrainian (23) 23
Swedish (20) 20
Norwegian (19) 19
Bulgarian (13) 13
Dutch (11) 11
Korean (8) 8
Turkish (6) 6
Romanian (5) 5
Finnish (4) 4
Serbian (4) 4
Croatian (3) 3
Hebrew (3) 3
Afrikaans (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chemical communications (Cambridge, England), ISSN 1359-7345, 11/2017, Volume 53, Issue 95, pp. 12834 - 12834
Correction for 'Direct N-H/α,α,β,β-C(sp 3 )-H functionalization of piperidine via an azomethine ylide route: synthesis of spirooxindoles bearing 3-substituted... 
Substitutes | Piperidine | Synthesis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Angewandte Chemie, ISSN 0044-8249, 02/2018, Volume 130, Issue 9, pp. 2283 - 2283
21 natürliche Bischinolizidin‐Alkaloide wurden nach einem modularen “Inside‐out”‐Ansatz hergestellt, den M. Breuning et al. in ihrer Zuschrift auf S. 2456... 
Piperidine
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 05/2016, Volume 75, Issue 5, pp. 831 - 841
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2017, Volume 376, Issue 18, pp. 1723 - 1736
Journal Article
Current topics in medicinal chemistry, ISSN 1568-0266, 01/2018, Volume 18, Issue 31, pp. 2731 - 2740
Background: Mycobacterium tuberculosis, Vibrio cholerae, and pathogenic Escherichia coli are global concerns for public health. The emergence of multi-drug... 
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Chlorogenic Acid - pharmacology | Drug Resistance, Multiple - drug effects | Escherichia coli - drug effects | Furans - pharmacology | Piper betle - chemistry | Structure-Activity Relationship | Lignans - pharmacology | Mycobacterium tuberculosis - drug effects | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Piperidines - pharmacology | Furans - chemistry | Anti-Bacterial Agents - chemistry | Carboxylic Acids - chemistry | Enzyme Inhibitors - chemistry | Furans - isolation & purification | Chlorogenic Acid - isolation & purification | Escherichia coli - metabolism | Molecular Structure | Escherichia coli - growth & development | Piperidines - isolation & purification | Mycobacterium tuberculosis - metabolism | Carboxylic Acids - pharmacology | Bacterial Proteins - antagonists & inhibitors | Piperidines - chemistry | Lignans - chemistry | Enzyme Inhibitors - pharmacology | Acetate Kinase - metabolism | Acetate Kinase - antagonists & inhibitors | Anti-Bacterial Agents - isolation & purification | Enzyme Inhibitors - isolation & purification | Lignans - isolation & purification | Acetate Kinase - genetics | Carboxylic Acids - isolation & purification | Bacterial Proteins - metabolism | Anti-Bacterial Agents - pharmacology | Molecular Docking Simulation | Chlorogenic Acid - chemistry | Mycobacterium tuberculosis - growth & development | Water-borne diseases | Pathogens | Multidrug resistance | Virulence | Chlorogenic acid | Carboxylic acids | Drug resistance | Kinases | Proteins | Microorganisms | Molecular modelling | Tuberculosis | Antibiotics | E coli | Bacteria | Docking | Acetate kinase | Piperidine | Acetic acid | Strains (organisms) | Public health | Vibrio
Journal Article
Nature (London), ISSN 1476-4687, 10/2013, Volume 503, Issue 7477, pp. 493 - 499
Adiponectin secreted from adipocytes binds to adiponectin receptors AdipoR1 and AdipoR2, and exerts antidiabetic effects via activation of AMPK and PPAR-alpha... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Liver - pathology | Obesity - drug therapy | Longevity - drug effects | Adipose Tissue, White - metabolism | Receptors, Adiponectin - metabolism | Diabetes Mellitus, Type 2 - metabolism | Muscle Fibers, Skeletal - drug effects | Obesity - genetics | Glucose Intolerance - drug therapy | Liver - drug effects | Piperidines - pharmacology | Inflammation - drug therapy | Adenylate Kinase - metabolism | Diet, High-Fat | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | Receptors, Adiponectin - agonists | Adiponectin - metabolism | Drug Evaluation, Preclinical | Diabetes Mellitus, Type 2 - complications | Adipose Tissue, White - pathology | Adiponectin - pharmacology | Dyslipidemias - drug therapy | Piperidines - administration & dosage | Administration, Oral | Obesity - complications | Piperidines - metabolism | Liver - metabolism | Diabetes Mellitus, Type 2 - prevention & control | Insulin Resistance | Obesity - physiopathology | Transcription Factors - biosynthesis | Mitochondria - metabolism | Mitochondria - drug effects | Enzyme Activation - drug effects | Triglycerides - metabolism | Small Molecule Libraries - chemistry | Receptors, Adiponectin - deficiency | Animals | Signal Transduction - drug effects | Piperidines - therapeutic use | Muscle Fibers, Skeletal - cytology | Mice | Oxidative Stress - drug effects | PPAR alpha - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Adipose Tissue, White - drug effects | Receptors, Adiponectin - genetics | Muscles - cytology | Obesity | Insulin resistance | Muscular system | Kinases | Rodents | Index Medicus
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 06/2017, Volume 77, Issue 9, pp. 1029 - 1034
Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of... 
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | United States | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Drug Approval | Indazoles - administration & dosage | Peritoneal Neoplasms - drug therapy | Piperidines - pharmacology | Adult | Female | Maintenance Chemotherapy | Ovarian Neoplasms - drug therapy | United States Food and Drug Administration | Fallopian Tube Neoplasms - drug therapy | Piperidines - administration & dosage | Double-Blind Method | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Randomized Controlled Trials as Topic | Indazoles - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Piperidines - therapeutic use | Piperidines - adverse effects | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indazoles - adverse effects | Indazoles - therapeutic use | Ovarian carcinoma | Homology | Metastasis | Neuroblastoma | Fallopian tube | Cancer therapies | DNA repair | Ovarian cancer | Ribose | Platinum | Cell cycle | Drug dosages | Deoxyribonucleic acid--DNA | Enzymes | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Breast cancer | Maintenance | Radiation therapy | Patients | Studies | Chemotherapy | Mutation | Solid tumors | Prostate cancer | Prostate | Tumors | Cancer | Apoptosis | Peritoneum | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 07/2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article